The findings reveal that COMP was positively correlated with a majority of immune inhibitors and stimulators in several cancers, with TNFSF4, an immune stimulator, and HAVCR2, an immune inhibitor, exhibiting the strongest correlation with COMP (Figure 7A). This evidence concerns the gene HAVCR2 and cancer.